Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
18230
Rush CM, Blanchard Z, Polaski JT, Osborne KS, Osby K, Vahrenkamp JM, Yang CH, Lum DH, Hagan CR, Leslie KK, Pufall MA, Thiel KW, Gertz J.
Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell lineSci Rep
2022
12(1):19731.
PubMed ID: 36396974
DOI: 10.1038/s41598-022-24211-8
8749
Matsumoto M, Yamaguchi Y, Seino Y, Hatakeyama A, Takei H, Niikura H, Ito K, Suzuki T, Sasano H, Yaegashi N, Hayashi S.
Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction.Endocr. Relat. Cancer
2008
15:451-63
PubMed ID: 18508998
DOI: 10.1677/ERC-07-0227
3796
Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.
Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.Int J Cancer
2003
107(1):53-9
PubMed ID: 12925956
DOI: 10.1002/ijc.11348